Cancer Vaccine

Vaccine that targets human chorionic gonadotropin extends colorectal cancer patient survival

Published in Vaccine Weekly, September 18th, 2002

by Maria G. Essig, MS, ELS, senior medical writer - Inoculation with a vaccine that generated an antibody response against human chorionic gonadotropin (hCG) increased survival of patients with colorectal cancer, researchers in the U.S. found.

"Human chorionic gonadotropin (hCG) is produced by colorectal cancer and may play a role in its progression," commented Hong M. Moulten and colleagues at AVI BioPharma, Inc., and the University of Alabama.

Moulton and his collaborators constructed an anti-hCG vaccine by conjugating the carboxyl terminal peptide of beta-hCG (CTP37) to diphtheria toxoid (DT). After formulating CTP37-DT into an emulsion, the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-09-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry